Astrazeneca's application for lung cancer treatment accepted by FDA

2nd Dec 2014 07:11

Astrazeneca said the US Food and Drug Administration (FDA) has accepted its new drug application for Iressa, a treatment designed for use in with a particular kind of lung cancer.It is already approved in 90 countries, having first been launched in 2002.Iressa acts by blocking the transmission of signals involved in the growth and spread of tumours.The group expects the goal date for the Prescription Drug User Fee Act, which levies a user fee on certain human drug applications, will be in the third quarter 2015.Shares were more or less flat at 4,705.54p in early deals on Tuesday.